Home › Compare › NBSE vs MCD

NBSE vs MCD: Dividend Comparison 2026

NBSE yields 529.10% · MCD yields 2.35%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NBSE wins by $95355.89M in total portfolio value
10 years
NBSE
NBSE
● Live price
529.10%
Share price
$0.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$95355.96M
Annual income
$69,511,989,565.27
Full NBSE calculator →
MCD
McDonald's Corporation
● Live price
2.35%
Share price
$308.53
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.5K
Annual income
$26,227.70
Full MCD calculator →

Portfolio growth — NBSE vs MCD

📍 NBSE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNBSEMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NBSE + MCD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NBSE pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NBSE
Annual income on $10K today (after 15% tax)
$44,973.54/yr
After 10yr DRIP, annual income (after tax)
$59,085,191,130.48/yr
MCD
Annual income on $10K today (after 15% tax)
$200.01/yr
After 10yr DRIP, annual income (after tax)
$22,293.55/yr
At 15% tax rate, NBSE beats the other by $59,085,168,836.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NBSE + MCD for your $10,000?

NBSE: 50%MCD: 50%
100% MCD50/50100% NBSE
Portfolio after 10yr
$47678.02M
Annual income
$34,756,007,896.48/yr
Blended yield
72.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

NBSE
Analyst Ratings
3
Buy
3
Hold
Consensus: Buy
Altman Z
-10.6
Piotroski
2/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+14.0% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NBSE buys
0
MCD buys
0
No recent congressional trades found for NBSE or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNBSEMCD
Forward yield529.10% ✓2.35%
Annual dividend / share$2.00$7.26 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3% ✓
Portfolio after 10y$95355.96M ✓$78.5K
Annual income after 10y$69,511,989,565.27 ✓$26,227.70
Total dividends collected$93138.90M ✓$58.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: NBSE vs MCD ($10,000, DRIP)

YearNBSE PortfolioNBSE Income/yrMCD PortfolioMCD Income/yrGap
1← crossover$63,610$52,910.05$10,815$334.85+$52.8K → NBSE
2$382,606$314,543.11$11,826$491.71+$370.8K → NBSE
3$2,177,551$1,768,162.86$13,123$730.06+$2.16M → NBSE
4$11,734,902$9,404,922.59$14,853$1,100.07+$11.72M → NBSE
5$59,924,074$47,367,729.01$17,257$1,690.61+$59.91M → NBSE
6$290,177,156$226,058,396.40$20,752$2,667.01+$290.16M → NBSE
7$1,333,544,009$1,023,054,452.33$26,103$4,354.83+$1333.52M → NBSE
8$5,820,882,501$4,393,990,410.63$34,794$7,437.78+$5820.85M → NBSE
9$24,153,246,984$17,924,902,708.82$49,926$13,461.60+$24153.20M → NBSE
10$95,355,963,839$69,511,989,565.27$78,550$26,227.70+$95355.89M → NBSE

NBSE vs MCD: Complete Analysis 2026

NBSE — Stock

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Full NBSE Calculator →

MCD — Consumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this NBSE vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NBSE vs SCHDNBSE vs JEPINBSE vs ONBSE vs KONBSE vs MAINNBSE vs YUMNBSE vs QSRNBSE vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.